Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma

Sorafenib, a multikinase inhibitor, is considered as the only approved drug to cure the advanced hepatocellular carcinoma (HCC); however, the acquired chemoresistance caused by intratumoral hypoxia through sorafenib long term therapy induces sorafenib inefficacy. We demonstrated here that hypoxia si...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Chao, Dong, Zhebin, Cai, Xianlei, Shen, Jie, Xu, Yuan, Zhang, Miaozun, Li, Hong, Yu, Weiming, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701149/
https://www.ncbi.nlm.nih.gov/pubmed/33250518
http://dx.doi.org/10.1038/s41419-020-03233-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701149/
https://www.ncbi.nlm.nih.gov/pubmed/33250518
http://dx.doi.org/10.1038/s41419-020-03233-y

Ejemplares similares